clinical trial · NCT04853251
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Genentech, Inc.·phase4·recruiting·n = 188
Neovascular Age-related Macular DegenerationPDS Implant With Ranibizumab 100 mg/mlLUCENTIS (Ranibizumab Injection)
brief summary
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
started
Dec 14, 2021
primary completion
Mar 31, 2028
completion
Apr 30, 2028
last updated
Apr 13, 2026
official title
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol